Literature DB >> 25873425

Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.

Zsolt Cselényi1,2, Lars Farde1,2.   

Abstract

Longitudinal positron emission tomography (PET) imaging of beta-amyloid is used in basic research and in drug efficacy trials in Alzheimer's disease (AD). However, the extent of amyloid accumulation after clinical onset is not fully known. Importantly, regional PET data are typically quantified using the standardized uptake value ratio (SUVR), which according to simulations is sensitive to changes in regional cerebral blood flow (rCBF). We aimed to better understand the potentials of longitudinal amyloid imaging by disentangling the influence of blood flow on SUVR using experimental data. [18F]AV-45 PET data from 101 subjects, ranging from cognitively normal to AD patients, in the Alzheimer's Disease Neuroimaging Initiative were extracted. The relationship between global cortical distribution volume ratio, indicator of rCBF (R1), and SUVR was examined using multilinear regression. There was a significant effect of rCBF on SUVR. The effect increased by disease severity. Results suggest that changes in rCBF can produce apparent changes in SUVR in AD. Therefore, future longitudinal studies should measure amyloid changes in a way not sensitive to this effect, ideally using quantitative PET imaging. Furthermore, the results suggest no true accumulation beyond clinical onset and highlight the risks of longitudinal amyloid imaging in drug trials in AD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25873425      PMCID: PMC4640337          DOI: 10.1038/jcbfm.2015.66

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

1.  Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.

Authors:  Stefan Förster; Timo Grimmer; Isabelle Miederer; Gjermund Henriksen; Behrooz Hooshyar Yousefi; Philipp Graner; Hans-Jürgen Wester; Hans Förstl; Alexander Kurz; Bradford C Dickerson; Peter Bartenstein; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2011-06-15       Impact factor: 13.382

2.  Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.

Authors:  Ahmadul Kadir; Ove Almkvist; Anton Forsberg; Anders Wall; Henry Engler; Bengt Långström; Agneta Nordberg
Journal:  Neurobiol Aging       Date:  2010-08-04       Impact factor: 4.673

3.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

4.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

5.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

Review 6.  Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Bruno P Imbimbo; Rosanna Tortelli; Andrea Santamato; Giancarlo Logroscino
Journal:  Expert Rev Clin Immunol       Date:  2014-02-04       Impact factor: 4.473

Review 7.  Current status of PET-imaging probes of β-amyloid plaques.

Authors:  Jaehyung Koo; Youngjoo Byun
Journal:  Arch Pharm Res       Date:  2013-07-01       Impact factor: 4.946

8.  Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.

Authors:  Ira Driscoll; Juan C Troncoso; Gay Rudow; Jitka Sojkova; Olga Pletnikova; Yun Zhou; Michael A Kraut; Luigi Ferrucci; Chester A Mathis; William E Klunk; Richard J O'Brien; Christos Davatzikos; Dean F Wong; Susan M Resnick
Journal:  Acta Neuropathol       Date:  2012-08-05       Impact factor: 17.088

Review 9.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

10.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Authors:  N M Scheinin; S Aalto; J Koikkalainen; J Lötjönen; M Karrasch; N Kemppainen; M Viitanen; K Någren; S Helin; M Scheinin; J O Rinne
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

View more
  14 in total

1.  Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue.

Authors:  Nathalie Mertens; Ralph Paul Maguire; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Koen Van Laere; Michel Koole
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  Subthreshold Amyloid Predicts Tau Deposition in Aging.

Authors:  Stephanie L Leal; Samuel N Lockhart; Anne Maass; Rachel K Bell; William J Jagust
Journal:  J Neurosci       Date:  2018-04-23       Impact factor: 6.167

3.  Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Authors:  Aurelija Jucaite; Per Stenkrona; Zsolt Cselényi; Serena De Vita; Nuria Buil-Bruna; Katarina Varnäs; Alicia Savage; Andrea Varrone; Peter Johnström; Magnus Schou; Chris Davison; Andy Sykes; Venkatesh Pilla Reddy; Matthias Hoch; Ana Vazquez-Romero; Mohammad Mahdi Moein; Christer Halldin; Melinda S Merchant; Martin Pass; Lars Farde
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

4.  EGF as a New Therapeutic Target for Medulloblastoma Metastasis.

Authors:  Jennifer Rico-Varela; Tanya Singh; Sean McCutcheon; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2015-06-04       Impact factor: 2.321

5.  Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease.

Authors:  Tomotaka Tanaka; Mary C Stephenson; Ying-Hwey Nai; Damian Khor; Francis N Saridin; Saima Hilal; Steven Villaraza; Bibek Gyanwali; Masafumi Ihara; Henri Vrooman; Ashley A Weekes; John J Totman; Edward G Robins; Christopher P Chen; Anthonin Reilhac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-20       Impact factor: 9.236

6.  Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451.

Authors:  Azadeh Firouzian; Alex Whittington; Graham E Searle; Ivan Koychev; Giovanna Zamboni; Simon Lovestone; Roger N Gunn
Journal:  EJNMMI Res       Date:  2018-03-02       Impact factor: 3.138

7.  Inflammatory projections after focal brain injury trigger neuronal network disruption: An 18F-DPA714 PET study in mice.

Authors:  Sanae Hosomi; Tadashi Watabe; Yuki Mori; Yoshihisa Koyama; Soichiro Adachi; Namiko Hoshi; Mitsuo Ohnishi; Hiroshi Ogura; Yoshichika Yoshioka; Jun Hatazawa; Toshihide Yamashita; Takeshi Shimazu
Journal:  Neuroimage Clin       Date:  2018-10-01       Impact factor: 4.881

8.  Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals.

Authors:  Tessa Timmers; Rik Ossenkoppele; Denise Visser; Hayel Tuncel; Emma E Wolters; Sander Cj Verfaillie; Wiesje M van der Flier; Ronald Boellaard; Sandeep Sv Golla; Bart Nm van Berckel
Journal:  J Cereb Blood Flow Metab       Date:  2019-10-01       Impact factor: 6.200

9.  A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease.

Authors:  Julie Ottoy; Jeroen Verhaeghe; Ellis Niemantsverdriet; Sebastiaan Engelborghs; Sigrid Stroobants; Steven Staelens
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

10.  Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept.

Authors:  Catherine J Scott; Jieqing Jiao; Andrew Melbourne; Ninon Burgos; David M Cash; Enrico De Vita; Pawel J Markiewicz; Antoinette O'Connor; David L Thomas; Philip Sj Weston; Jonathan M Schott; Brian F Hutton; Sébastien Ourselin
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-05       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.